Prostate-specific antigen: How to advise patients as the screening debate continues

Cleveland Clinic Journal of Medicine

Volumn 72, Issue 6, 2005, Pages 521-527

  Albertsen, Peter C ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AFRICAN AMERICAN; ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER MORTALITY; CANCER SCREENING; FAMILY HISTORY; HEALTH CARE COST; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; MALE; PATIENT EDUCATION; PROSTATE BIOPSY; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 21344441227     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.72.6.521     Document Type: Article

References (19)

1. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324:1156-1161.
2. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29.
3. Ries L, Eisner M, Kosary C, et al. SEER cancer statistics review, 1973-1997. Bethesda, MD: National Cancer Institute, 2000. (NIH publication no. 00-2789.)
4. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA 2004; 291:2713-2719.
5. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994,330:242-248.
6. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280:975-980.
7. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273:289-294.
8. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level of < 4.0 ng per milliliter. N Engl J Med 2004; 350:2239-2246.
9. Eastham JA, Riedel E, Scardino PT, et al. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 2004; 289:2695-2700.
10. Oliver SE, Gunnell D, Donovan JL. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet 2000; 355:1788-1789.
11. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360:103-106.
12. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341:1781-1788.
13. Holmberg L, Bill-Axelson & Helegsen F, et al, for the Scandinavian Prostatic Cancer Group Study Number 4. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002; 347:781-789.
14. Welch HG, Schwartz LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA 2000; 283:2975-2978.
15. Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The Prostate Outcomes Study. JAMA 2000; 283:354-360.
16. United States Preventive Services Task Force. Screening for prostate cancer: recommendations and rationale. Ann Intern Med 2002; 137:915-916.
17. Ross KS, Carter HB, Pearson JD, Guess HA. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA 2000; 284:1399-1405.
18. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95:868-878.
19. Frosch DL, Kaplan RM, Felitti VJ. A randomized controlled trial comparing Internet and video to facilitate patient education for men considering the prostate specific antigen test. J Gen Intern Med 2003: 18:781-787.